Cadila Healthcare has reported results for third quarter ended December 31, 2017.
The company has reported around 14-fold jump in its net profit at Rs 306.40 crore for the quarter under review as compared to Rs 22 crore for the same quarter in the previous year. Total income of the company increased by 97.87% to Rs 1631.80 crore for Q3FY18 as compared Rs 824.70 crore for the corresponding quarter previous year.
On consolidate basis, the company has reported 67.74% rise in its net profit after taxes, Non-Controlling Interests and Share of Profits of Joint Ventures at Rs 543.30 crore for the quarter ended December 31, 2017 as compared to Rs 323.90 crore for the corresponding quarter in the FY17. Total consolidated income of the company increased by 38.66% at Rs 3300.70 crore for quarter under review as compared to Rs 2380.40 crore for the same quarter ended previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: